A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs BL-B01D1 (Primary)
Indications Head and neck cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Sichuan Baili Pharmaceutical

18 Dec 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
18 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
10 Sep 2024 Planned End Date changed from 1 Aug 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com